In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.

One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that ...